

DOCKET NO. NEU-041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Singleton et al.

Serial No.: 09/991,293

Art Unit: 1654

Filed : November 16, 2001

Examiner: Patricia Patten

For : Composition Containing Peptides Complexed with Copper Ions

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner of Patents, Washington, D.C. 20231 on

May 7, 2004

(Date of Deposit)

William E. McGowan

(Name of applicant, assignee, or Registered Representative)

(Signature)

May 7, 2004

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**VERIFIED STATEMENT UNDER 37 CFR §1.821(f)**

Dear Sir:

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/991,293

States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,


By: 

William E. McGowan  
Reg. No. 39,301

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2197  
Dated: May 7, 2004

DOCKET NO. NEU-041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Singleton et al.

Serial No.: 09/991,293

Art Unit: 1654

Filed : November 16, 2001

Examiner: Patricia Patten

For : Composition Containing Peptides Complexed with Copper Ions

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner of Patents, Washington, D.C. 20231 on

May 7, 2004

(Date of Deposit)

William E. McGowan

(Name of applicant, assignor, or Registered Representative)

A handwritten signature in black ink, appearing to read "W. McGowan", written over a horizontal line.

(Signature)

May 7, 2004

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE**

Dear Sir:


Pursuant to the requirements of 37 CFR 1.822 and 1.823 and further to the Formalities Letter mailed March 8, 2004, Applicant submits a corrected copy of the Sequence Listing in computer readable form, including a printed version of the Sequence Listing of the subject application. As required, a copy of the Formalities Letter is also attached.

Furthermore, a Verified Statement concerning the enclosed diskette, and a preliminary amendment are submitted herewith.

Serial No. 09/991,293

If any fees are due in connection with the filing of this response, authorization is hereby given to charge the amount of such fee to Deposit Account No. 10-0750-/NEU-41/WEM in the name of Johnson & Johnson.


Respectfully submitted,

By:   
William E. McGowan  
Reg. No. 39,301

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2197  
Dated: May 7, 2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**